Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 16, 2023 - Issue
Submit an article Journal homepage
304
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization

Jonathan Corren1 David Geffen School of Medicine at UCLA, Los Angeles, CA, USACorrespondence[email protected]
,
David J Jackson2 King’s College London, London, UK;3 Guy’s and St Thomas’ NHS Foundation Trust, London, UK
,
Thomas B Casale4 Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA
,
Larry Borish5 Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA;6 Carter Immunology Center, University of Virginia Health System, Charlottesville, VA, USA
,
Klaus F Rabe7 LungenClinic Grosshansdorf (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany;8 Christian-Albrechts University (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, GermanyORCID Iconhttps://orcid.org/0000-0002-7020-1401
ORCID Icon,
William W Busse9 UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USAORCID Iconhttps://orcid.org/0000-0003-2591-4696
ORCID Icon,
Jorge F Maspero10 Fundación CIDEA, Buenos Aires, Argentina
,
Daniel J Jackson11 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
,
Nadia Daizadeh12 Sanofi, Cambridge, MA, USA
,
Arman Altincatal12 Sanofi, Cambridge, MA, USA
,
Amr Radwan13 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
,
Angela Khodzhayev13 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
,
Michel Djandji12 Sanofi, Cambridge, MA, USA
,
Juby A Jacob-Nara12 Sanofi, Cambridge, MA, USA;14 Sanofi, Bridgewater, NJ, USA
,
Paul J Rowe14 Sanofi, Bridgewater, NJ, USA
&
Yamo Deniz13 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
 show all
Pages 249-260 | Received 09 Aug 2022, Accepted 30 Jan 2023, Published online: 07 Mar 2023

Figures & data

Table 1 Baseline Demographics, Disease Characteristics, and Biomarker Levels of Patients with a Type 2 Phenotype (Blood Eosinophils ≥150 Cells/µL or FeNO ≥25 ppb) Who Were Sensitized to 1, 2, 3, or ≥4 Perennial Aeroallergens, or Non-Sensitized, at QUEST Baseline

Figure 1 Adjusted annualized severe exacerbation rates in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by sensitization. *P < 0.05, **P < 0.01, ***P < 0.001 vs matched combined placebo.

Abbreviations: CI, confidence interval; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E; IU, international units; ppb, parts per billion.
Figure 1 Adjusted annualized severe exacerbation rates in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by sensitization. *P < 0.05, **P < 0.01, ***P < 0.001 vs matched combined placebo.

Figure 2 Pre-bronchodilator FEV1 over time in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by aeroallergen sensitization (A-E). *P < 0.05, **P < 0.01, ***P < 0.001 vs matched combined placebo.

Abbreviations: FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; LS, least squares; ppb, parts per billion; SE, standard error.
Figure 2 Pre-bronchodilator FEV1 over time in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by aeroallergen sensitization (A-E). *P < 0.05, **P < 0.01, ***P < 0.001 vs matched combined placebo.

Figure 3 ACQ-5 score over time in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by sensitization (A-E). *P < 0.05, **P < 0.01, ***P < 0.001 vs matched placebo.

Abbreviations: ACQ-5, 5-item Asthma Control Questionnaire; FeNO, fractional exhaled nitric oxide; LS, least squares; ppb, parts per billion; SE, standard error.
Figure 3 ACQ-5 score over time in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by sensitization (A-E). *P < 0.05, **P < 0.01, ***P < 0.001 vs matched placebo.

Figure 4 Median (95% CI) FeNO over time in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by sensitization (A-E). *P < 0.05, **P < 0.01, ***P < 0.001 vs matched placebo.

Abbreviations: CI, confidence interval; FeNO, fractional exhaled nitric oxide; ppb, parts per billion.
Figure 4 Median (95% CI) FeNO over time in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by sensitization (A-E). *P < 0.05, **P < 0.01, ***P < 0.001 vs matched placebo.

Figure 5 Median (95% CI) serum total IgE over time in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by sensitization (A-E). **P < 0.01, ***P < 0.001 vs matched placebo.

Abbreviations: CI, confidence interval; FeNO, fractional exhaled nitric oxide; ppb, parts per billion.
Figure 5 Median (95% CI) serum total IgE over time in patients with ≥150 eosinophils/µL or FeNO ≥25 ppb by sensitization (A-E). **P < 0.01, ***P < 0.001 vs matched placebo.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.